Applications of Fibroblast Activation Protein Inhibitor-PET in Interventional Oncology
- PMID: 40300985
- DOI: 10.1016/j.cpet.2025.03.004
Applications of Fibroblast Activation Protein Inhibitor-PET in Interventional Oncology
Abstract
Molecular imaging-guided techniques increase precision in surgical procedure and reduce postinterventional morbidity. Fibroblast activation protein (FAP) ligands may contribute to the superior preoperative assessment compared with conventional radionuclides due to its higher sensitivity and tumor delineation in epithelial malignancies. Wide spectrum of currently available FAP ligands including diagnostic and therapeutic emitters allows a flexibility regarding the optimal choice for individual need. Moreover, newly introduced hybrid tracers with fluorescence-based FAP probes enrich this spectrum by providing intraoperative FAP-targeting without radiation exposure. Thus, the use of FAP ligands in interventional oncology has great promise in improving the efficiency of local-interventional surgery.
Keywords: FAPI; Fibroblast activation protein; Interventional oncology; PET; Theranostics.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure F.L. Giesel has a patent application for quinolone-based FAP-targeting agents for imaging and therapy in nuclear medicine and shares of a consultancy group for iTheranostics. F.L. Giesel is also advisor at ABX, Telix, Alpha Fusion, and SOFIE Biosciences. The other authors declare no conflict of interest regarding this article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
